SCHEMBL7066427

SCHEMBL7066427

Cc1ccc(C(=O)CN2CC=CC(c3cc(CCCOc4ccccc4)n[nH]3)=C2Cl)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 1/20 0.34
HRH1 P35367 1/20 0.34
LMNA P02545 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MCL1 Q07820 3/20 0.31
ALDH1A1 P00352 2/20 0.31
CASP3 P42574 2/20 0.31
SENP8 Q96LD8 2/20 0.31
SENP7 Q9BQF6 2/20 0.31
SENP6 Q9GZR1 2/20 0.31
POLB P06746 1/20 0.31
HPGD P15428 1/20 0.31
BCL2 P10415 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6596187 0.73 KMT2A (0.35) HRH2HRH1LMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL1193915 0.72 KMT2A (0.35) HRH2HRH1LMNAMEN1KMT2A
SCHEMBL660037 0.66 NPC1 (0.36) LMNAMEN1KMT2AMAPTMAPK1
SCHEMBL662688 0.62 ALDH1A1 (0.35) LMNAMEN1KMT2AMAPTMAPK1
SCHEMBL660157 0.61 HTT (0.33) MEN1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL16231967 0.59 GPR84 (0.49) MCL1ALDH1A1NPC1RAB9A
SCHEMBL9937687 0.56 HPGDS (0.56) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL10805742 0.55 POLB (0.40) LMNAMEN1KMT2AMAPTMAPK1
SCHEMBL21341647 0.54 ALDH1A1 (0.52) LMNAMAPTMAPK1SMN1; SMN2ALDH1A1
SCHEMBL17833256 0.53 MAPT (0.63) LMNAMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030045554-A1 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof TORRENT PHARMACEUTICALS LTD. 2003-03-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045554-A1 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof AGER, GLA, F12 HRH2 2185/4885HRH1 1852/4885LMNA 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.